Sequent Scientific to acquire Solara Active Pharma Sciences' EU-GMP API facility at Mahad
Capital MarketSequent Scientific has entered into a Business transfer agreement with Solara Active Pharma Sciences to acquire the EU-GMP API facility at Mahad (Mahad facility). The total consideration for the unit would be Rs 46.4 crore on an Enterprise Valuation basis.
The acquired Mahad facility compliments the company's current manufacturing at Vizag (USFDA approved) and Tarapur (Intermediates).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
